{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:00:06Z","timestamp":1776088806843,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100022937","name":"Australian and New Zealand Head and Neck Cancer Society","doi-asserted-by":"publisher","award":["2021, Trudi Shine Adenoid Cystic Carcinoma Fund"],"award-info":[{"award-number":["2021, Trudi Shine Adenoid Cystic Carcinoma Fund"]}],"id":[{"id":"10.13039\/501100022937","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The tumour-cell based initiation of immune evasion project evaluated the role of Gipie in adenoid cystic carcinoma (ACC)\u00a0and mucoepidermoid carcinoma (A-253), from ninety-six 3D-ACC and A-253-immune co-culture models using\u00a0natural killer cells (NK), and Jurkat cells (JK). Abnormal ACC morphology was observed in 3D-ACC immune co-culture models. Gipie-silencing conferred a \u201clymphoblast-like\u201d morphology to ACC cells, a six-fold increase in apoptotic cells (compared to unaltered ACC cells, <jats:italic>P<\/jats:italic>\u2009\u2264\u20090.0001), a two-fold decrease in T regulatory cells (FoxP3<jats:sup>+<\/jats:sup>\/IL-2R\u03b1<jats:sup>+<\/jats:sup>\/CD25<jats:sup>+<\/jats:sup>) (<jats:italic>P<\/jats:italic>\u2009\u2264\u20090.0001), and a three-fold increase in activated NK cells (NKp30<jats:sup>+<\/jats:sup>\/IFN-\u03b3<jats:sup>+<\/jats:sup>) (<jats:italic>P<\/jats:italic>\u2009\u2264\u20090.0001) with significantly higher release of granzyme (<jats:italic>P<\/jats:italic>\u2009\u2264\u20090.001) and perforin (<jats:italic>P<\/jats:italic>\u2009\u2264\u20090.0001).<\/jats:p>","DOI":"10.1038\/s41598-023-44329-7","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T18:03:02Z","timestamp":1696874582000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Preclinical 3D-model supports an invisibility cloak for adenoid cystic carcinoma"],"prefix":"10.1038","volume":"13","author":[{"given":"Rajdeep","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charbel","family":"Darido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aidan","family":"Tay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Vickery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honghua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoba","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"key":"44329_CR1","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1084\/jem.20140455","volume":"211","author":"J Kennedy","year":"2014","unstructured":"Kennedy, J. et al. CCDC88B is a novel regulator of maturation and effector functions of T cells during pathological inflammation. J Exp Med. 211, 2519\u20132535 (2014).","journal-title":"J Exp Med."},{"issue":"6","key":"44329_CR2","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1002\/JLB.3A0420-386R","volume":"108","author":"JF Olivier","year":"2020","unstructured":"Olivier, J. F. et al. CCDC88B is required for mobility and inflammatory functions of dendritic cells. J. Leukoc. Biol. 108(6), 1787\u20131802 (2020).","journal-title":"J. Leukoc. Biol."},{"key":"44329_CR3","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.4049\/jimmunol.1402897","volume":"194","author":"H Ham","year":"2015","unstructured":"Ham, H. et al. HkRP3 is a microtubule-binding protein regulating lytic granule clustering and NK cell killing. J. Immunol. 194, 3984\u20133996 (2015).","journal-title":"J. Immunol."},{"issue":"1","key":"44329_CR4","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/s41467-017-01381-y","volume":"8","author":"N Fodil","year":"2017","unstructured":"Fodil, N. et al. CCDC88B is required for pathogenesis of inflammatory bowel disease. Nat. Commun. 8(1), 932 (2017).","journal-title":"Nat. Commun."},{"key":"44329_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.oraloncology.2018.10.012","volume":"87","author":"KA Warner","year":"2018","unstructured":"Warner, K. A. et al. UM-HACC-2A: MYB-NFIB fusion-positive human adenoid cystic carcinoma cell line. Oral Oncol. 87, 21\u201328 (2018).","journal-title":"Oral Oncol."},{"issue":"2","key":"44329_CR6","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1182\/blood-2004-10-4035","volume":"106","author":"M Vitale","year":"2005","unstructured":"Vitale, M. et al. NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood 106(2), 566\u2013571 (2005).","journal-title":"Blood"},{"key":"44329_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s42003-019-0322-9","volume":"2","author":"H Colin-York","year":"2019","unstructured":"Colin-York, H. et al. Cytoskeletal actin patterns shape mast cell activation. Commun. Biol. 2, 93 (2019).","journal-title":"Commun. Biol."},{"key":"44329_CR8","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/nri1983","volume":"12","author":"I Voskoboinik","year":"2006","unstructured":"Voskoboinik, I. et al. Perforin-mediated target-cell death and immune homeostasis. Nat. Rev. Immunol. 12, 940\u2013952 (2006).","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"44329_CR9","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/cdd.2009.206","volume":"17","author":"SP Cullen","year":"2010","unstructured":"Cullen, S. P. et al. Granzymes in cancer and immunity. Cell Death Differ. 17(4), 616\u201323 (2010).","journal-title":"Cell Death Differ."},{"issue":"2","key":"44329_CR10","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-11-1872","volume":"72","author":"T Placke","year":"2012","unstructured":"Placke, T. et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 72(2), 440\u2013448 (2012).","journal-title":"Cancer Res."},{"issue":"1","key":"44329_CR11","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1038\/s41467-017-02230-8","volume":"8","author":"FY Cabrales","year":"2017","unstructured":"Cabrales, F. Y. et al. Multivalent cross-linking of actin filaments and microtubules through the microtubule-associated protein Tau. Nat. Commun. 8(1), 1981 (2017).","journal-title":"Nat. Commun."},{"issue":"3","key":"44329_CR12","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1091\/mbc.01-08-0398","volume":"13","author":"S Edlund","year":"2002","unstructured":"Edlund, S. et al. Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol. Biol. Cell 13(3), 902\u2013914 (2002).","journal-title":"Mol. Biol. Cell"},{"issue":"4","key":"44329_CR13","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle, E. & Massagu\u00e9, J. Transforming growth factor-\u03b2 signaling in immunity and cancer. Immunity 50(4), 924\u2013940 (2019).","journal-title":"Immunity"},{"issue":"1","key":"44329_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s12672-022-00502-4","volume":"13","author":"R Farhat","year":"2022","unstructured":"Farhat, R. et al. Pembrolizumab as a first line therapy in a patient with extensive mucoepidermoid salivary gland carcinoma. A complete clinical, radiological and pathological response. A very specific case. Discov. Oncol. 13(1), 37 (2022).","journal-title":"Discov. Oncol."},{"issue":"8","key":"44329_CR15","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1158\/2326-6066.CIR-16-0031","volume":"4","author":"V Sridharan","year":"2016","unstructured":"Sridharan, V. et al. Immune profiling of adenoid cystic carcinoma: PD-L2 expression and associations with tumor-infiltrating lymphocytes. Cancer Immunol. Res. 4(8), 679\u2013687 (2016).","journal-title":"Cancer Immunol. Res."},{"issue":"16","key":"44329_CR16","doi-asserted-by":"publisher","first-page":"6048","DOI":"10.1200\/JCO.2023.41.16_suppl.6048","volume":"41","author":"M Mohamadpour","year":"2023","unstructured":"Mohamadpour, M. et al. A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent\/metastatic adenoid cystic carcinoma. J. Clin. Oncol. 41(16), 6048\u20136048 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"44329_CR17","first-page":"a006189","volume":"8","author":"RR Pharaon","year":"2022","unstructured":"Pharaon, R. R. et al. Prolonged response to checkpoint inhibitor therapy in two metastatic mucoepidermoid salivary gland carcinoma cases: A research report. Cold Spring Harb Mol Case Stud. 8(3), a006189 (2022).","journal-title":"Cold Spring Harb Mol Case Stud."},{"issue":"1","key":"44329_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/cr.2009.139","volume":"20","author":"JR Dunkelberger","year":"2010","unstructured":"Dunkelberger, J. R. et al. Complement and its role in innate and adaptive immune responses. Cell Res. 20(1), 34\u201350 (2010).","journal-title":"Cell Res."},{"issue":"8","key":"44329_CR19","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41568-021-00363-z","volume":"21","author":"D Briukhovetska","year":"2021","unstructured":"Briukhovetska, D. et al. Interleukins in cancer: From biology to therapy. Nat. Rev. Cancer 21(8), 481\u2013499 (2021).","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"44329_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13148-022-01336-1","volume":"14","author":"SC Liu","year":"2022","unstructured":"Liu, S. C. et al. PDCD5 inhibits progression of renal cell carcinoma by promoting T cell immunity: With the involvement of the HDAC3\/microRNA-195\u20135p\/SGK1. Clin. Epigenet. 14(1), 131 (2022).","journal-title":"Clin. Epigenet."},{"issue":"10","key":"44329_CR21","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/j.1600-0463.2010.02669.x","volume":"118","author":"B Lauenborg","year":"2010","unstructured":"Lauenborg, B. et al. Programmed cell death-10 enhances proliferation and protects malignant T cells from apoptosis. APMIS 118(10), 719\u2013728 (2010).","journal-title":"APMIS"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44329-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44329-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44329-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T20:18:51Z","timestamp":1700252331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44329-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["44329"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-44329-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,9]]},"assertion":[{"value":"15 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17033"}}